Neuromyelitis optica spectrum disorders(NMOSD)is a recurrent disease with significant neurological deficits,which can seriously affect the quality of life of patients.In recent years,the interleukin-6 receptor suppressor suterizumab has shown outstanding performance in the treatment of NMOSD,which can effectively reduce the recurrence rate and have fewer adverse drug reactions.This article reviews the mechanism,efficacy and adverse drug reactions of suterizumab in the treatment of NMOSD.
维普
万方数据